Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial - Tesch, Hans; Marmé, Frederik; Schneeweiss, Andreas (International journal of cancer, 2019)
Online 11 Jul 2018